Skip to main content

Table 3 Number of doses received during each cycle of HD IL-2

From: A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

Cycle

Group

n

Mean

Min

Max

1

Prior Ipi

52

9.9

3

14

No ICB

276

9.9

1

14

2

Prior Ipi

49

8.2

1

14

No ICB

252

8.2

2

14

3

Prior Ipi

17

8.2

5

12

No ICB

98

8.6

1

14

4

Prior Ipi

17

6.7

2

12

No ICB

88

6.6

2

14